Hengrui Pharma to exceed $10B in revenue by 2028

Hengrui Pharma will likely exceed $10 billion in annual revenue by 2028 due to the commercialization of the licensed cancer drug and pipeline expansion. The $15B deal provides significant capital and market access to drive growth.

Implied probability (Yes)

70%